Moderate to severe OSA was associated with increased risk for severe and critical COVID-19, particularly in those with severe intermittent hypoxia.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.